Product Information
CLIND PH-BENZOYL PERO 1.2-2.5% is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.8191 per GM under NDC 45802059701. Its NADAC has been published 356 times since Dec 11, 2019.
FDA first approved this application on Sep 9, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 10 mg/g; mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802059701
Classification
Generic
Dosage Form
GEL
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEApproval Type
Generic (ANDA)
FDA Application
ANDA205397FDA Approved
9/9/2019
TE Code
AB
On Market Since
9/12/2019
Pharmacological Classes
Price Statistics
The NADAC for CLIND PH-BENZOYL PERO 1.2-2.5% has been published 356 times since Dec 11, 2019, and over the history we have for it it has declined 88.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8191 per GM |
|---|---|
| All-time high | $7.4004 (Mar 11, 2020) |
| All-time low | $0.6671 (Jul 22, 2026) |
| 52-week high | $0.9869 |
| 52-week low | $0.6671 |
| Median price | $1.2892 |
| Average price | $1.5719 |
| Largest weekly change | +71.0% (Feb 22, 2023) |
| Weeks tracked | 356 |
| Tracking since | Dec 11, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Clindamycin Phosphate, Benzoyl Peroxide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clindamycin Phosphate, Benzoyl Peroxide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLIND PH-BENZOYL PERO 1.2-2.5%?
The current National Average Drug Acquisition Cost (NADAC) for CLIND PH-BENZOYL PERO 1.2-2.5%, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.8191 per GM (NDC 45802059701), effective Sep 30, 2026.
How has the price of CLIND PH-BENZOYL PERO 1.2-2.5% changed over time?
Over the history we have for it, the NADAC for CLIND PH-BENZOYL PERO 1.2-2.5% has declined 88.9%. It has been tracked across 356 weekly CMS publications since Dec 11, 2019.
What are the highest and lowest recorded NADAC prices for CLIND PH-BENZOYL PERO 1.2-2.5%?
Since Dec 11, 2019, the NADAC for CLIND PH-BENZOYL PERO 1.2-2.5% has ranged from a low of $0.6671 (Jul 22, 2026) to a high of $7.4004 (Mar 11, 2020), with a median of $1.2892 per GM.
Are there cheaper alternatives to CLIND PH-BENZOYL PERO 1.2-2.5%?
No other NADAC-published product currently shares the active ingredient and strength of CLIND PH-BENZOYL PERO 1.2-2.5% in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CLIND PH-BENZOYL PERO 1.2-2.5%?
CLIND PH-BENZOYL PERO 1.2-2.5% (NDC 45802059701) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.